{"Title":"Clementia Pharmaceuticals","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"24","Founded":"","Address":"","Phone":"(514) 940-3600","Web_address":"http://www.clementiapharma.com","Market_cup":"$415.5mil","Revenues":"$16.6 mil (last 12 months)","Net_income":"$-92.8 mil (last 12 months)","Symbol":"CMTA","Exchange":"NASDAQ","Shares":"8.0","Price_range":"$15.00 - $15.00","Est_volume":"$120.0 mil","Manager":"Morgan Stanley/ Leerink Partners","CO_managers":"Wedbush Securities/ BTIG","Exp_to_trade":"8/2/2017","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a clinical stage biopharmaceutical company that is developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Our lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. We are developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO) and have one registration trial and one Phase 2/3 clinical trial for two separate indications planned to commence in 2017 with data read-outs planned in 2019 and 2020."}